Luttmer, Roosmarijn
De Strooper, Lise M A
Dijkstra, Maaike G
Berkhof, Johannes
Snijders, Peter J F
Steenbergen, Renske D M
van Kemenade, Folkert J
Rozendaal, Lawrence
Helmerhorst, Theo J M
Verheijen, René H M
ter Harmsel, W Abraham
van Baal, W Marchien
Graziosi, Peppino G C M
Quint, Wim G V
Spruijt, Johan W M
van Dijken, Dorenda K E
Heideman, Daniëlle A M
Meijer, Chris J L M
Article History
Received: 17 March 2016
Revised: 31 May 2016
Accepted: 2 June 2016
First Online: 14 July 2016
Competing interests
: JB has played an advisory role for Merck and Roche, has been on the speakers bureau of Qiagen and has received a travel reimbursement from DDL Diagnostic Laboratory. PJFS has been on the speakers bureau of Roche, Qiagen, Abbott, Gen-Probe and Seegene. PJFS is consultant for Crucell Holland BV. TJMH, RHMV and WAH have been principal investigators of a GlaxoSmithKline sponsored study. WGVQ is a minority shareholder of Diassay BV and obtained grants from GlaxoSmithKline. DAMH has been on the speakers bureau of Hologic/Gen-Probe and serves occasionally on the scientific advisory boards of AMGEN and Pfizer. CJLMM has been on the sponsored speakers bureau of GlaxoSmithKline, Qiagen, Merck, Roche, Menarini and Segeene, and served on the scientific advisory board of GlaxoSmithKline, Qiagen, Merck and Roche. CJLMM has been consultant for Qiagen and Genticel and is a minority shareholder of Diassay BV. Formerly, CJLMM was a minority shareholder of Delphi Biosciences. CJLMM, PJFS, RDMS and DAMH have minority stake in Self-screen BV, a spin-off company of VU University Medical Center Amsterdam, which holds patents related to the present work. RL, LMADS, MGD, FJvK, LR, WMvB, GCMG, JWMS and DKEvD do not have any conflict of interest to declare.